Why the study?
Cardiotoxic therapies impair cardiac function and cardiorespiratory fitness in breast cancer survivors, prompting the need to summarize the effects of exercise training and how to adapt traditional approaches.
Does exercise training improve cardiorespiratory fitness and cardiac function in breast cancer survivors undergoing cardiotoxic therapy?
Does exercise training improve cardiorespiratory fitness and cardiac function in breast cancer survivors undergoing cardiotoxic therapy?
Exercise training is an effective strategy to mitigate the decline in cardiorespiratory fitness and potentially preserve cardiac function in breast cancer survivors exposed to cardiotoxic therapies.
Supports CORe during chemotherapy to attenuate LVEF decline in BCS; extends RCT evidence for exercise in cardio-oncology.
PURPOSE: Improvements in diagnosis and treatment mean that the long-term health of breast cancer survivors (BCS) is increasingly dictated by cardiovascular comorbidities. This is partly a consequence of exposure to cardiotoxic therapies, which result in cardiac dysfunction and decreased cardiorespiratory fitness (CRF). Exercise training (ExT) is a key therapeutic strategy for secondary prevention and increasing CRF in adults with established cardiovascular disease. Exercise-based cardio-oncology rehabilitation (CORE) has been proposed as an emerging strategy to address CRF and cardiac impairment in BCS. This review aims to (1) provide an overview of the impact of breast cancer therapy on CRF; (2) provide an up-to-date summary of the effects of ExT on CRF and cardiac function in BCS undergoing cardiotoxic therapy; and (3) discuss how traditional ExT approaches can be adapted for BCS undergoing therapy. REVIEW METHODS: A literature review was performed based on an intensive literature search for systematic reviews and meta-analyses, randomized and non-randomized controlled trials and single-arm trials investigating the impact of exercise training or cardiac rehabilitation on CRF and/or cardiac function in BCS who are undergoing or have completed cardiotoxic cancer therapy. SUMMARY: Overall, current evidence suggests that ExT induces clinically meaningful benefits for CRF in BCS during and after therapy. There is also emerging evidence that ExT can improve peak exercise measures of cardiac function; however, there is a need for further research to understand how to adapt these effective ExT approaches into clinical CORE-based settings.
No takes yet. Share an insight, caveat, or question.
Foulkes et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: